Clinical Trials Browser

Phase 3 × cemiplimab × 30 days × Clear all

NCT06931717 2026-06-01

ARCH

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3 Completed

789 enrolled 32 charts 1 FDA

Carcinoma, Non-Small-Cell Lung